Diabetic Ketoacidosis as a Delayed Immune-Related Event after Discontinuation of Nivolumab
Nivolumab, an anti-programmed cell death-1 (PD-1) monoclonal antibody with immune checkpoint inhibitory activity, represents a novel treatment for several cancers. Immune checkpoint inhibitors cause side effects, known as immune-related adverse events (irAEs) or delayed immune-related events (DIRE), after immunotherapy discontinuation. Type 1 diabetes mellitus (T1DM) and diabetic ketoacidosis have been reported to develop as an irAE during the treatment with nivolumab. Here, we report on a patient who developed T1DM and diabetic ketoacidosis after discontinuation of treatment with nivolumab as a DIRE.
Source: The Journal of Emergency Medicine - Category: Emergency Medicine Authors: Soichiro Mae, Akira Kuriyama, Hiromi Tachibana Tags: Selected Topics: Oncological Emergencies Source Type: research
More News: Cancer | Cancer & Oncology | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Emergency Medicine | Endocrinology | Immunotherapy